Gonorrhea Diagnostic Market by Types (Molecular Diagnostics Tests, Flow Cytometry, Diagnostic Imaging, Liposomes, Artificial Intelligence, Gel Micro-droplets, Chromatography, Differential Light Scattering, and Monoclonal Antibodies) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global gonorrhea diagnostics market size is anticipated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing number of various sexually transmitted diseases all around the world and the growing demand for rapid diagnosis tools.

Gonorrhea is a sexually transmitted disease (STD) caused by the virus, Neisseria gonorrhoeae, an inflammation of the mucous membrane surface. Both men and women are vulnerable to the virus. Furthermore, the infection thrives in the moist and warmth areas of the female reproductive track such as the cervix, uterus, and fallopian tube. However, many men and women do not have any gonorrhoea symptoms in majority of cases. When an infected person develops symptoms, they are often similar to those of another bacterial disorder, which further makes it difficult to distinguish between the two. However, some of the commonly occurred symptoms of the disease are penile and vaginal discharge, frequent urine discharge, burning feeling while peeing, and, less commonly enlarged testicles. Intercourse, as well as anal or oral sex, can spread the disease infection.

Due to the COVID-19 pandemic outbreak, the gonorrhea diagnostic market is adversely impacted. However, all major precautions are taken to treat STD, followed by prescribed guidelines. Alternatively, patients are encouraged telemedicine consultation for follow-ups as hospitals & clinics are minimizing the contacts between patients & staffs for the treatment.

Market Trends, Drivers, Restraints, and Opportunities

• Ongoing government initiatives and rising technologically advanced products in the field of diagnostics are some of the key factors propelling the market growth.
• Increasing successful rate in providing accurate results and rising population having multiple casual sex partners are another important factors fueling the market expansion in the coming years.
• Growing expenditure on healthcare infrastructure and increasing various R&D activities on gonorrhea therapeutics are expected to boost the market growth.
• High cost involved in manufacturing advanced diagnostic devices and implementing stringent regulatory policies are expected to hamper market growth.
• Ongoing social stigma about visiting the clinics regarding sexual diseases is anticipated to be a key restraining factor hindering the market expansion.
• Growing awareness related to the disease and treatment along with increasing investment on the development of accurate & efficient treatment for sexually transmitted diseases are anticipated to offer tremendous opportunity during the forecast period.

Scope of Gonorrhea Diagnostic Market Report

The report on the global gonorrhea diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Gonorrhea Diagnostic Market Segment Insights

Molecular diagnosis segment is expected to grow at a rapid pace

Based on types, the global gonorrhea diagnostics market is segregated into molecular diagnostics tests, flow cytometry, diagnostic imaging, liposomes, artificial intelligence, gel micro-droplets, chromatography, differential light scattering, and monoclonal antibodies. The molecular diagnosis segment is expected to grow at a rapid pace during the forecast period owing to the easy performing procedure, high accuracy rate, and cost-effective treatment.

However, modern approaches such as artificial intelligence and diagnostic imaging are still in the testing stages, but they are projected to account for a large market share during the forecast period. Newer technologies for faster and more accurate infection detection are anticipated to replace the old techniques of diagnosis in the future gonorrhea diagnostic market.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the projected period owing to wide prevalence of the disease in the region. According to the Centers for Disease Control and Prevention (CDC), approximately 820,000 new cases of gonorrhea are getting diagnosed in the United States each year, making it the most frequent infectious disease among young people.

Furthermore, around 70% of the population out of these 820,000 new cases is estimated to be between the ages of 15 to 24. According to the CDC, women aged 25 and over are at a higher risk of contracting gonorrhea. Unprotected sex, many sex partners, and oral or anal sex with a STD infected individual are all risk factors for this disease. Thus, aforementioned factors are expected to propel the market growth in the region.

Segments

The global gonorrhea diagnostic market has been segmented on the basis of

Types

• Molecular Diagnostics Tests
• Flow Cytometry
• Diagnostic Imaging
• Liposomes
• Artificial Intelligence
• Gel Micro-droplets
• Chromatography
• Differential Light Scattering
• Monoclonal Antibodies

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• bioMérieux
• Tosoh Corp.
• PerkinElmer, Inc.
• Siemens AG
• Ortho Clinical Diagnostics
• F. Hoffmann-La Roche AG
• Beckman Coulter Inc.
• Abbott Laboratories

Competitive Landscape

Some of the major companies competing in the global gonorrhea diagnostics market are bioMérieux; Tosoh Corp.; PerkinElmer, Inc.; Siemens AG; Ortho Clinical Diagnostics; F. Hoffmann-La Roche AG; Beckman Coulter Inc.; and Abbott Laboratories. These major players are implementing various marketing strategies such as capital investments, merger & acquisitions, and new product development to enhance their market position in the regional competition.

For example, in May 2019, Hologic, Inc. has gained FDA 510 (k) approval for its Aptima Combo 2 Assays, a gonorrhoea and chlamydia diagnostic test. It was one of the first gadgets to be approved for sexually transmitted disease testing. Furthermore, Binx health has received 510 (k) clearance from the US Food and Drug Administration (FDA) in August 2019 for their quick point-of-care platform binx io. The binx io platform was aimed at utilizing to detect chlamydia and gonorrhoea.